Market Snapshot
| Study Period: | 2018 - 2026 |
| Base Year: | 2021 |
| Fastest Growing Market: | Asia Pacific |
| Largest Market: | North America |
| CAGR: | 19.27 % |
|
Need a report that reflects how COVID-19 has impacted this market and its growth?
Market Overview
The global computational biology market is expected to grow with a CAGR of 19.27%. Factors that are responsible for the growth of the market include increase in bioinformatics research, increasing number of clinical studies in pharmacogenomics and pharmacokinetics, and growth of drug designing and disease modeling.
Bioinformatics is recognized as part of the essential knowledge base of numerous career paths in biomedical research and healthcare. The field of bioinformatics and computational biology has gone through a number of transformations over the past 15 years, establishing itself as a key component of new biology. The use of bioinformatics tools in life sciences has become necessary to analyze experimental data. The huge amounts of data pose a challenge for the biological community, as most biologists are not familiar with informatics and statistical interpretation. An interdisciplinary collaboration was started with an aim to address the need for biologists to understand biological data.
Recent improvements in bioinformatics include capacity-building through activities, such as research funding and training opportunities. Increased funding in bioinformatics is helping in creating more advancements in the field of computational biology.
Scope of the Report
As per the scope, computational biology involves the development and application of data-analytical and theoretical methods, mathematical modeling and computational simulation techniques to the study of biological, ecological, behavioral, and social systems. Computational biology uses biological data for developing algorithms to understand biological systems and relationships. by Application (Cellular and Biological Simulation, Drug Discovery and Disease Modelling, Preclinical Drug Development, Clinical Trials and Human Body Simulation Software), Tool (Databases, Infrastructure (Hardware), Analysis Software and Services), Service (In-house and Contract), End User (Academics and Industry and Commercials) and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD million) for the above segments.
| Application | ||||||
| ||||||
| ||||||
| ||||||
| ||||||
| Human Body Simulation Software |
| By Tool | |
| Databases | |
| Infrastructure (Hardware) | |
| Analysis Software and Services |
| By Service | |
| In-house | |
| Contract |
| By End User | |
| Academics | |
| Industry and Commercials |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Key Market Trends
Industry and Commercials Sub-segment is Expected to hold its Highest Market Share in the End User Segment
In the end user segment of the market, the Industry and Commercials sub-segment is believed to have the largest market size and is expected to witness a CAGR of 19.50% during the forecast period.
Computational biology has a wide range of applications in the fields of genomics, proteomics, pharmacogenomics, and drug discovery. For drug discovery and clinical trials, many companies approach third-party services, who have to maintain computational biology setups for carrying out various drug discovery processes. Many third-party services and small laboratories that maintain computational biology setups are expected to gain huge profits, as they successfully reduce the overall time needed for drug discovery and various other scientific experiments.
The software and databases are relatively costlier, and the cost of drug discovery processes vary across countries, which makes many industries opt for outsourcing, thereby, leading to an increased demand for small laboratories and other commercial companies. Hence, with the increase in bioinformatics research, the increasing number of clinical studies in pharmacogenomics and pharmacokinetics, and the growth of drug designing, disease modeling, and personalized medicine, the demand for computational biology for industry and commercial purposes is expected to increase, thereby, driving the market during the forecast period.
To understand key trends, Download Sample Report
North America Dominates the Market and is Expected to do the Same in the Forecast Period
North America currently dominates the market for computational biology and is expected to continue its stronghold for a few more years. The United States is the leading nation in the field of synthetic biology, which is an emerging discipline involving the creation, control, and reprogramming of biological systems. Since 2005, the US government has channelled more than USD 1 billion for the development of computational biology and synthetic biology. The annual average expenditure for the development of computational biology, by the United States government, has been estimated to be USD 140 million.
The overall market for computational biology in the United States is scheduled to grow manifold, over the forecast period, primarily due to high expenditure in drug development endeavors (highest in the world).
To understand geography trends, Download Sample Report
Competitive Landscape
The computational biology market is expected to become highly competitive in the near future, as it consists of several major players. With increasing technological advancements and product innovations, mid-size to smaller companies are increasing their market presence by introducing new products with fewer prices. Companies, like Dassault Systèmes, Chemical Computing Group Inc., Instem Plc. (Leadscope Inc.), Compugen Ltd, and Certara, hold substantial shares in the market.
Recent Developments
- In April 2021, Peptilogics, a biotechnology platform company leveraging computational design to discover novel peptide therapeutics, announced the successful completion of a Phase 1 clinical trial for its lead compound PLG0206, a potent, broad-spectrum anti-infective that has been granted FDA Orphan Drug Designation and Qualified Infectious Disease Product Designation for its initial focus on the treatment of prosthetic joint infections (PJI).
- In January 2021, AsclepiX Therapeutics Inc., a biopharmaceutical company using computational biology to identify potent peptide regulators of vascular and cellular homeostasis for the treatment of retinal and oncologic diseases, announced that the first patient has been dosed in the Phase 1/2a CONGO clinical trial to evaluate the safety and bioactivity of AXT107 in patients with Diabetic Macular Edema (DME).
Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increase in Bioinformatics Research
4.2.2 Increasing Number of Clinical Studies in Pharmacogenomics and Pharmacokinetics
4.2.3 Growth of Drug Designing and Disease Modeling
4.3 Market Restraints
4.3.1 Lack of Trained Professionals
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
5.1 Application
5.1.1 Cellular and Biological Simulation
5.1.1.1 Computational Genomics
5.1.1.2 Computational Proteomics
5.1.1.3 Pharmacogenomics
5.1.1.4 Other Cellular and Biological Simulations (Transcriptomics/Metabolomics)
5.1.2 Drug Discovery and Disease Modelling
5.1.2.1 Target Identification
5.1.2.2 Target Validation
5.1.2.3 Lead Discovery
5.1.2.4 Lead Optimization
5.1.3 Preclinical Drug Development
5.1.3.1 Pharmacokinetics
5.1.3.2 Pharmacodynamics
5.1.4 Clinical Trials
5.1.4.1 Phase I
5.1.4.2 Phase II
5.1.4.3 Phase III
5.1.5 Human Body Simulation Software
5.2 By Tool
5.2.1 Databases
5.2.2 Infrastructure (Hardware)
5.2.3 Analysis Software and Services
5.3 By Service
5.3.1 In-house
5.3.2 Contract
5.4 By End User
5.4.1 Academics
5.4.2 Industry and Commercials
5.5 Geography
5.5.1 North America
5.5.1.1 United States
5.5.1.2 Canada
5.5.1.3 Mexico
5.5.2 Europe
5.5.2.1 Germany
5.5.2.2 United Kingdom
5.5.2.3 France
5.5.2.4 Italy
5.5.2.5 Spain
5.5.2.6 Rest of Europe
5.5.3 Asia-Pacific
5.5.3.1 China
5.5.3.2 Japan
5.5.3.3 India
5.5.3.4 Australia
5.5.3.5 South Korea
5.5.3.6 Rest of Asia-Pacific
5.5.4 Middle East & Africa
5.5.4.1 GCC
5.5.4.2 South Africa
5.5.4.3 Rest of Middle East & Africa
5.5.5 South America
5.5.5.1 Brazil
5.5.5.2 Argentina
5.5.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Dassault Systèmes SE
6.1.2 Certara
6.1.3 Chemical Computing Group ULC
6.1.4 Compugen Ltd
6.1.5 Rosa & Co. LLC
6.1.6 Genedata AG
6.1.7 Insilico Biotechnology AG
6.1.8 Instem Plc. (Leadscope Inc.)
6.1.9 Nimbus Discovery LLC
6.1.10 Strand Life Sciences
6.1.11 Schrodinger
6.1.12 Simulation Plus Inc.
*List Not Exhaustive7. MARKET OPPORTUNITIES AND FUTURE TRENDS
You can also purchase parts of this report. Do you want to check out a section wise price list?
Frequently Asked Questions
What is the study period of this market?
The Computational Biology Market market is studied from 2018 - 2026.
What is the growth rate of Computational Biology Market?
The Computational Biology Market is growing at a CAGR of 19.27% over the next 5 years.
Which region has highest growth rate in Computational Biology Market?
Asia Pacific is growing at the highest CAGR over 2021- 2026.
Which region has largest share in Computational Biology Market?
North America holds highest share in 2020.
Who are the key players in Computational Biology Market?
Dassault Systèmes SE, Chemical Computing Group ULC, Genedata AG, Instem PLC , Compugen Ltd are the major companies operating in Computational Biology Market.
